Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)
Enrolling by invitation · NCT05962398
Conditions: Hemophilia B
At a glance
- Research payments reported, 2025
- $421,639
- U.S. investigators named
- 16
- Sites paid
- 15
- Planned or actual enrollment
- 56
About the trial
- Sponsor
- CSL Behring
- Tested
- AAV5-hFIXco-Padua (genetic)
- Dates
- Started 2023-08-30; completion 2035-03-23
- Results posted
- Not yet
The primary purpose of this study is to assess the long-term safety and efficacy in male adults with hemophilia B who were treated with CSL222 (CSL222) in parent studies CSL222\_2001 (NCT03489291) or CSL222\_3001 (NCT03569891).
From ClinicalTrials.gov, last updated 2025-07-18. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Csl Behring reported $421,639 in research payments for this study in 2025 (132 payments).
Products named: Hemgenix
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Shelley E. Crary, MD Pediatric Hematology & Oncology · Little Rock, AR
- Christine M. Knoll, M.D. Pediatric Hematology & Oncology · Phoenix, AZ
- Shanna L. White, M.D. Pediatric Hematology & Oncology · Phoenix, AZ
- Adam Giermasz, M.D., PHD Hematology & Oncology · Sacramento, CA
- Doris Quon, M.D. Hematology · Los Angeles, CA
- Annette Von Drygalski, MD Hematology & Oncology · San Diego, CA
- Guy A. Young, M.D. Pediatric Hematology & Oncology · Los Angeles, CA
- Tyler W. Buckner, M.D. Hematology · Aurora, CO
- Bradley S. Fletcher, MD Hematology · Tampa, FL
- Steven W. Pipe, MD Pediatric Hematology & Oncology · Ann Arbor, MI
- Nigel S. Key, MD Hematology & Oncology · Chapel Hill, NC
- Kristina M. Haley, DO Pediatric Hematology & Oncology · Portland, OR
- Shannon C. Walker, M.D. Pathology · Nashville, TN
- Miguel A. Escobar, M.D. Hematology · Houston, TX
- Richard S. Lemons Pediatric Hematology & Oncology · Salt Lake City, UT
- Rebecca Kruse-jarres, M.D. Hematology & Oncology · Seattle, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- University of North Carolina at Chapel Hill $93,189
- University of Utah Hospital and Clinics, UT $80,572
- University of California Davis Medical Center, CA $52,681
- Ohsu Hospital and Clinics, OR $33,143
- Vanderbilt University Medical Center, TN $24,814
- Arkansas Children's Research Institute $21,561
- University of Michigan Health System, MI $21,317
- Washington Institute for Coagulation $18,449
- University of South Florida $16,640
- Regents of the University of California San Diego $16,194
- Children's Hosp of Los Angeles, CA $15,498
- The University of Texas Health Science Center at Houston $12,361
- Phoenix Children's Hospital, AZ $12,188
- Regents of the University of Colorado dba Exsera Biolabs $3,014
- Orthopaedic Institute for Children $18
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.